Data from clinical trials have demonstrated substantial improvements in heart failure (HF) hospitalization and cardiovascular mortality among heart failure patients treated with SGLT2 inhibitors, irrespective of their diabetes status [8,9]. This evidence concerns the gene SLC5A2 and hydrops fetalis.